Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record.

334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity

Abstract

Background: Weight loss is the cornerstone of therapy for people with overweight/obesity. Pemvidutide is a dual GLP-1/glucagon receptor agonist that provides GLP-1/glucagon agonism in a balanced (1:1) ratio, which is hypothesized to enhance weight loss and minimize gastrointestinal intolerance. Methods: 34 subjects with overweight/obesity (BMI 25.0-40.0 kg/m2) without diabetes were randomized in double-blind manner to pemvidutide (1.2, 1.8 or 2.4 mg) or placebo subcutaneously weekly for 12 weeks without dose titration or lifestyle therapy. Study endpoints included safety/tolerability, weight loss and cardiometabolic outcomes. Results: At 12 weeks, significant weight loss was achieved with 1.8 mg (10.3%) and 2.4 mg (9.0%) of pemvidutide, and significant improvements or trends in cardiometabolic risk factors were observed at all pemvidutide doses (Table 1) . No increases in heart rate, fasting glucose or HbA1c were observed in any group. Mild, transient nausea was the most frequent adverse event (AE) ; no severe/serious AEs or AE-related study discontinuations were reported. Conclusion: Pemvidutide induces robust weight loss and improves cardiometabolic risk factors without dose titration. These data support the development of pemvidutide as a promising treatment for obesity and its comorbidities. Disclosure: S.Klein: Advisory Panel; Altimmune, Consultant; Janssen Research & Development, LLC, ProSciento, Research Support; Janssen Research & Development, LLC. S.K.Browne: Employee; Altimmune. J.J.Nestor: Consultant; Altimmune, Employee; EuMederis Pharmaceutials, Inc., Mederis Diabetes, LLC, Spitfire Pharma, Inc. M.Harris: Employee; Altimmune. A.Suyundikov: Employee; Altimmune. R.Casper: Employee; Altimmune. S.M.Steele: Employee; Altimmune. J.D.Payne: None. V.Krishnan: Employee; Altimmune. M.Roberts: Employee; Altimmune. Funding: Altimmune, Inc.

Overview

Integrity signals

Registry

Crossref · 10.2337/db22-334-or

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Still being checked.

Cited by

See all 22

Metadata

Authors
KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K.
Affiliations
St. Louis, MO, South San Francisco, CA, Gaithersburg, MD
Venue
Diabetes
Published
2022-06-01
Volume
71
Issue
Supplement_1
ISSN
0012-1797 (ISSN-L)
OpenAlex
W4281699715
Cited by
21
References
0
Citations by year
2026: 1 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 1
FWCI
3.00
Type
journal article
Language
en
Open access
closed
Locations
Diabetes (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
Keywords
obesity, overweight, weight loss, cardiometabolic risk factors, nausea, dose titration, drug safety and tolerability

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: 334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity. https://app.cochat.ai/papers/10.2337/db22-334-or
The paper
KLEIN, S., NESTOR, J. J., HARRIS, M. S., SUYUNDIKOV, A., CASPER, R., STEELE, S. M., PAYNE, J. D., KRISHNAN, V., ROBERTS, M. S., & BROWNE, S. K. (2022). 334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight/obesity. Diabetes. https://doi.org/10.2337/db22-334-or

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.